Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV
-
The HoT study: an essential new study with the potential to significantly expand the body of knowledge around menopause among women living with HIV
-
ACTG today announced the publication of “Tecovirimat for the Treatment of Mpox (STOMP)" in NEJM.
-
ACTG today announced the publication of “Cabotegravir plus Rilpivirine for Persons Living with HIV" in the NEJM.
-
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study.
-
Treating people living with HIV and metabolic dysfunction-associated MASLD with semaglutide significantly improved biomarkers of cardiovascular risk.
-
ACTG Presents Findings from REPRIEVE at CROI 2025 Presentations Address Frailty, Inflammation, Asymptomatic Heart Muscle Damage, and Mental Function
-
ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV
-
ACTG Presents Data from Mpox Study STOMP at CROI
-
Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects